LH Laboratory Corporation of America Holdings

LabCorp Named Among “The World’s Most Innovative Companies” in Forbes’ 2017 Ranking

LabCorp® (NYSE: LH), a leading global life sciences company, has been named to Forbes’ 2017 ranking of “The World’s Most Innovative Companies.”

“Innovation in guiding patient care is what we do at LabCorp, so being recognized as one of the world’s most innovative companies by Forbes is a tremendous honor to our more than 57,000 dedicated colleagues,” said David P. King, chairman and CEO of LabCorp. “I am proud of the cutting-edge work that they do every day, allowing LabCorp to bring innovative solutions to our customers, and to carry out our mission of improving health and improving lives.”

According to the consultants who co-created the list with Forbes: “Most innovation rankings are popularity contests based on past performance or editorial whims. We set out to create something very different with the World’s Most Innovative Companies list, using the wisdom of the crowd. Our method relies on investors’ ability to identify firms they expect to be innovative now and in the future.”

To qualify for consideration on the list, firms must have $10 billion in market cap and seven years of public financial data. Companies are ranked by an “innovation premium” tied to market cap, cash flows, and investors’ expectations of “profitable new growth.” The complete list is available at www.forbes.com/innovative-companies.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

This press release contains forward-looking statements about the Company’s future operations. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

EN
07/09/2017

Underlying

Reports on Laboratory Corporation of America Holdings

Labcorp Holdings Inc: 1 director

A director at Labcorp Holdings Inc sold 5,745 shares at 262.750USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Moody's Ratings affirms Laboratory Corporation of America's Baa2 backe...

Moody's Ratings (Moody's) affirmed Laboratory Corporation of America Holdings' ("Labcorp") Baa2 backed senior unsecured debt rating. At the same time, we revised the outlook to stable from positive. The revision of outlook reflects our expectation of the company's continued acquisition-led busines...

Moody's Ratings assigns Baa2 rating to Laboratory Corporation of Ameri...

Moody's Ratings (Moodys) assigned a Baa2 rating to Laboratory Corporation of America Holdings' ("Labcorp") proposed offering of backed senior unsecured notes of up to $1.8 billion. Labcorp intends to use the net proceeds from this offering, along with drawings from a new accounts receivables (A/R) s...

Laboratory Corporation of America Holdings: Update to credit analysis

Our credit view of this issuer reflects its significant scale and strong market position, against its low organic volume growth in a mature industry.

Laboratory Corporation of America Holdings: Update to credit analysis

Our credit view of this issuer reflects its significant scale and strong market position, against its low organic volume growth in a mature industry.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch